| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 19th October 2020 | Mark Alan Goldberg | 5,455 | Exercise of derivative | $19.53 | $106,536.15 |
| 19th October 2020 | Mark Alan Goldberg | 5,455 | Open or private sale | $105.00 | $572,775.00 |
| 16th October 2020 | Kate Haviland | 3,125 | Open or private sale | $101.56 | $317,375.00 |
| 16th October 2020 | Kate Haviland | 13,334 | Exercise of derivative | $36.05 | $480,690.70 |
| 16th October 2020 | Kate Haviland | 3,009 | Open or private sale | $102.53 | $308,512.77 |
| 16th October 2020 | Kate Haviland | 7,200 | Open or private sale | $100.55 | $723,960.00 |
| 7th October 2020 | Jeffrey W. Albers | 5,000 | Open or private sale | $99.17 | $495,850.00 |
| 7th October 2020 | Jeffrey W. Albers | 5,000 | Exercise of derivative | $8.80 | $44,000.00 |
| 7th October 2020 | Mark Alan Goldberg | 5,454 | Open or private sale | $100.00 | $545,400.00 |
| 7th October 2020 | Mark Alan Goldberg | 5,454 | Exercise of derivative | $19.53 | $106,516.62 |
Blueprint Medicines
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.
Ticker: BPMC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1597264
Employees: 383
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $289 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $568 M (9%)
Property, Plant and Equipment, Net: $37 M (0%)
Other Assets, Noncurrent: $8 M (-18%)
Assets: $817 M (15%)
Accounts Payable, Current: $6 M (16%)
Accrued Liabilities, Current: $84 M (0%)
Liabilities, Current: $105 M (-1%)
Other Liabilities, Noncurrent: $9 M (9%)
Liabilities: $236 M (-2%)
Common Stock, Value, Issued: $54 Th (10%)
Common Stock, Shares, Issued: $54 M (10%)
Retained Earnings (Accumulated Deficit): $1 B (24%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-55%)
Stockholders' Equity (Parent): $581 M (0%)
Liabilities and Equity: $817 M (15%)
Cost of Revenue: $127 Th (-15%)
Research and Development: $91 M (-48%)
Other Income, net: $2 M (-63%)
News
Just in Time, the Retribution Gods Are Catching Up with Trumpworld
24th October 2020
Top Stocks To Short Today As Markets Pace To End Week With Losses
23rd October 2020